In particular, Aradhye noted "increasing progress" at all levels of the innovation supply chain in China — "whether it's ...

Novartis has agreed to partner on developing additional molecular glue degraders (MGDs) for immune-mediated diseases, in an expanded collaboration that could generate more than $5.7 billion for the ...

Structurally-guided discovery using high-resolution cryo-EM has delivered potent, DCAF16-dependent Targeted Glues™ of SMARCA2, with exquisite ...

Following a meeting between the two parties on Wednesday, it is now up to the Federal Court to decide what the Swiss cross ...

In all, 1,088 bottles of Chasselas wine were uncorked simultaneously in the Swiss village of Chardonne on Saturday.

Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models ...

Leg-spinner Yuzvendra Chahal's maiden six-wicket for India as the hosts beat England by 75 runs in the third and final Twenty20 International ...

Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics agreed to an up to $5.7 billion licensing deal to develop ...

Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to US$5.7 billion on ...

Novartis on Tuesday said it was buying a U.S. biotech working on a cardiovascular drug, continuing what’s been a flurry of ...

Monte Rosa stock soars 38% after a $5.7B Novartis partnership to develop AI-powered degraders for immune diseases. Read more ...

The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to ...